{
    "clinical_study": {
        "@rank": "151227", 
        "arm_group": {
            "arm_group_label": "myopic LASIK procedure", 
            "arm_group_type": "Other", 
            "description": "All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight\u00ae FS200 Femtosecond Laser and the WaveLight\u00ae Allegretto Wave\u00ae Eye-Q Laser"
        }, 
        "brief_summary": {
            "textblock": "Evaluate visual outcomes and contrast sensitivity for subjects undergoing bilateral myopic\n      LASIK procedure using the 200 kHz WaveLight\u00ae FS200 Femtosecond Laser and the WaveLight\u00ae\n      Allegretto Wave\u00ae Eye-Q Laser.  The use of advanced technology may decrease the loss of\n      contrast sensitivity and improvement of postoperative visual acuity results."
        }, 
        "brief_title": "Visual Outcomes and Contrast Sensitivity After Myopic LASIK", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": "Myopia", 
        "condition_browse": {
            "mesh_term": "Myopia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA\n\n          -  Male or female in good general health, 18 years of age or older at the time of the\n             pre-operative examination\n\n          -  Patient must be able to read, comprehend and willing to give HIPPA and informed\n             consent\n\n          -  Patient is planning to undergo a bilateral LASIK procedure\n\n          -  Both eyes must have a manifest refractive error from -1.00 D to -7.00 spherical\n             equivalent with less than or equal to 3.00D of refractive astigmatism as expressed in\n             spectacle minus cylinder form\n\n          -  Both eyes must have a BSCVA of 20/20 or better\n\n          -  Both eyes must demonstrate refractive stability confirmed by clinical records,\n             previous glasses, or investigator's discretion.\n\n          -  Patient must be willing to comply with study dosing and complete the entire course of\n             the study.\n\n        EXCLUSION CRITERIA\n\n          -  A patient with evidence of keratoconus, corneal irregularity, or abnormal\n             videokeratography in either eye\n\n          -  A patient seeking monovision\n\n          -  A patient with a known hypersensitivity to any of the components of the procedural or\n             post-LASIK medications\n\n          -  A patient requiring the use of any ocular drop(s) and/or medication(s) in either eye\n             during the study period with the exception of ocular drops and/or medications\n             provided by the investigator\n\n          -  A patient having any surgical procedure within a week preceding the scheduled LASIK\n             surgery\n\n          -  A patient with any UNCONTROLLED systemic disease (i.e., a potential patient in whom\n             therapy for a systemic disease is not yet stabilized )\n\n          -  A patient with a history of prior intraocular or corneal surgery (including cataract\n             extraction), active clinically significant ophthalmic disease or abnormality\n             (including, but not limited to, blepharitis, recurrent corneal erosion, dry eye\n             syndrome, neovascularization > 1mm from limbus), clinically significant lens opacity,\n             clinical evidence of trauma (including scarring) inside the visual axis, or evidence\n             of glaucoma or propensity for narrow angle glaucoma in either eye\n\n          -  A patient with a significant history or current evidence of a medical, psychological\n             or other disorder that, in the investigator's opinion, may increase the risk\n             associated with study participation or may interfere with the interpretation of study\n             results\n\n          -  A patient with a history of any of the following medical conditions, or any other\n             condition that could affect wound healing: uncontrolled diabetes, collagen vascular\n             disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or\n             simplex, endocrine disorders (including, but not limited to unstable thyroid\n             disorders and diabetes), lupus, and rheumatoid arthritis\n\n          -  Current participation or participation within 30 days prior to the start of this\n             study in a drug or other investigational research study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746589", 
            "org_study_id": "FS200SVR-10-2011"
        }, 
        "intervention": {
            "arm_group_label": "myopic LASIK procedure", 
            "description": "200 kHz WaveLight\u00ae FS200 Femtosecond Laser and the WaveLight\u00ae Allegretto Wave\u00ae Eye-Q Laser", 
            "intervention_name": "bilateral myopic LASIK", 
            "intervention_type": "Device", 
            "other_name": "WaveLight\u00ae Femtosecond Laser and WaveLight\u00ae Allegretto\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "LASIK", 
        "lastchanged_date": "January 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66211"
                }, 
                "name": "Durrie Vision"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT\u00ae FS200 Femtosecond Laser and the WAVELIGHT\u00ae ALLEGRETTO WAVE\u00ae EYE-Q Laser", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in uncorrected visual acuity from baseline, postoperatively, immediately(1-3 minutes) after surgery, 30 minutes, 1 hour, 2 hours, 4 hours, 1 day, and 1 month.", 
            "measure": "Change in Uncorrected Visual Acuity over time postoperatively", 
            "safety_issue": "No", 
            "time_frame": "Postoperatively immediate (1-3 minutes), 30 minutes, 1 hour, 2 hours, 4 hours, 1 day, and 1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746589"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Durrie Vision", 
            "investigator_full_name": "Daniel S. Durrie, MD", 
            "investigator_title": "President", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Contrast sensitivity (ability to distinguish between shades of gray) will be measured postoperatively immediately (1-3 minutes) after surgery, 30 minutes,1 hour, 2 hours, 4 hours, 1 day, and 1 month.", 
            "measure": "Change in contrast sensitivity postoperatively as compared to baseline", 
            "safety_issue": "No", 
            "time_frame": "Postoperatively at immediately (1-3 minutes) after surgery, 30 minutes, 1 hour, 2 hours, 4 hours, 1 day and 1 month"
        }, 
        "source": "Durrie Vision", 
        "sponsors": {
            "collaborator": {
                "agency": "Alcon Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Daniel S. Durrie, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}